Positive News SentimentPositive NewsNASDAQ:QCLS Mymd Pharmaceuticals (QCLS) Stock Price, News & Analysis $1.71 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$1.65 -0.06 (-3.51%) As of 05:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesSEC Filings About Mymd Pharmaceuticals Stock (NASDAQ:QCLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mymd Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.65▼$1.7750-Day Range$1.65▼$3.8552-Week Range$1.64▼$8.94Volume238,318 shsAverage Volume218,156 shsMarket Capitalization$14.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview MyMD Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes. The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation. MyMD Pharmaceuticals is based in the United States and has operated as a research-driven biotechnology company centered on bringing new therapeutic options to market. Because company details can change over time and reliable, up-to-date information on leadership and current geographic operations is limited, this description is intentionally brief and limited to broadly verifiable business information.AI Generated. May Contain Errors. Read More Mymd Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreQCLS MarketRank™: Mymd Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat, and ranked 536th out of 595 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingMymd Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMymd Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Mymd Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mymd Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mymd Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMymd Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.47% of the float of Mymd Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMymd Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Mymd Pharmaceuticals has recently decreased by 1.16%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMymd Pharmaceuticals does not currently pay a dividend.Dividend GrowthMymd Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentMymd Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mymd Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for QCLS on MarketBeat in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mymd Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.86% of the stock of Mymd Pharmaceuticals is held by insiders.Percentage Held by Institutions9.64% of the stock of Mymd Pharmaceuticals is held by institutions.Read more about Mymd Pharmaceuticals' insider trading history. Receive QCLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mymd Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QCLS Stock News HeadlinesQ/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) DevelopmentAugust 4, 2026 | globenewswire.comQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJuly 1, 2026 | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJune 30, 2026 | globenewswire.comSee More Headlines QCLS Stock Analysis - Frequently Asked Questions How have QCLS shares performed this year? Mymd Pharmaceuticals' stock was trading at $4.33 on May 15, 2026. Since then, QCLS stock has decreased by 60.5% and is now trading at $1.71. How were Mymd Pharmaceuticals' earnings last quarter? Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) posted its earnings results on Wednesday, August, 12th. The company reported ($0.79) EPS for the quarter. How do I buy shares of Mymd Pharmaceuticals? Shares of QCLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2026Today9/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 QCLS's financial health is in the Yellow zone, according to TradeSmith. QCLS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Technology Hardware, Storage & Peripherals Sub-IndustryTechnology Hardware, Storage & Peripherals Current SymbolNASDAQ:QCLS CIK1321834 Webtnfpharma.com Phone(856) 848-8698Fax856-848-0269Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-91.64% Return on Assets-47.48% Debt Debt-to-Equity RatioN/A Current Ratio3.29 Quick Ratio3.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book0.33Miscellaneous Outstanding Shares8,190,000Free Float8,120,000Market Cap$14.00 million OptionableN/A Beta2.09 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:QCLS) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mymd Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mymd Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QCLS Stock Alerts